Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HA-ADH@IR808
- Development stage
- Preclinical
- Lead developer
- Jinan University
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**HA-ADH@IR808** is an experimental, CD44-targeted hyaluronic acid-adipic acid dihydrazide micellar nanotherapeutic incorporating the near-infrared cyanine photothermal agent IR808. It was reported for image-guided mild photothermal therapy of **triple-negative breast cancer** in preclinical models. Hyaluronic acid promotes tumor-cell uptake through CD44, which is enriched on cancer stem cell populations, while IR808 converts near-infrared laser energy into localized heat. The hydrazide-containing micelle also produces chemical exchange saturation transfer signals that support intratumoral mapping of the formulation and treatment-temperature monitoring. In mouse studies, mild photothermal treatment inhibited tumor growth and metastatic potential, with reported depletion of CD44-positive cells and reduced collagen I-associated epithelial-mesenchymal transition signaling.
- Other names
- HA-ADH@IR808
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on HA-ADH@IR808.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HA-ADH@IR808.